Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute (Other)

Overall Status

Completed

CT.gov ID

NCT01324180

Collaborator

Pediatric Cancer Foundation (Other)

Enrollment

Locations

Arm

72.3

Actual Duration (Months)

2.8

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project Coordinator, but will not be recruiting locally.

The purpose of the trial is to study the clinical and biological effects of metformin in combination with standard systemic chemotherapy in a disease (relapsed ALL) that has a dismal outcome, as well as to do a dose escalation study to find the Maximum Tolerated Dose (MTD) of metformin in conjunction with ALL therapy. There have also been analysis of patients enrolled on trials who were diabetics on metformin and their outcome was better than patients on the same trial that were not on metformin as their antihyperglycemic.

Condition or Disease	Intervention/Treatment	Phase
Acute Lymphoblastic Leukemia	Drug: Metformin Drug: Vincristine Drug: Dexamethasone Drug: PEG-asparaginase Drug: Doxorubicin Drug: Intrathecal chemotherapy	Phase 1

Detailed Description

This will be a phase I protocol of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and metformin conducted in the Sunshine Project sites for children with recurrent ALL. All sites will be eligible to open this study, provided they agree to adhere to all study procedures and make a good faith effort to obtain all pharmacodynamic and pharmacokinetic evaluations requested.

Study Design

Study Type:

Interventional

Actual Enrollment :

14 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination With Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin With Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD)

Actual Study Start Date :

Jul 18, 2011

Actual Primary Completion Date :

Nov 16, 2016

Actual Study Completion Date :

Jul 27, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: VLPD Regimen Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.	Drug: Metformin Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner. Drug: Vincristine 1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23 Other Names: Oncovin® VCR LCR NSC #67574 Drug: Dexamethasone 10 mg/m^2/day divided BID Take dexamethasone by mouth days 2-15 Other Names: Decadron® Hexadrol® Dexone® Dexameth® NSC #34521 (112004) Drug: PEG-asparaginase 2500 IU's/m^2/day Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23 If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis. Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol. Other Names: Oncaspar NSC #644954 Pegaspargase Oncaspar® Polyethylene Glycol Conjugated L-asparaginase-H Drug: Doxorubicin 60 mg/m^2/day IV over 15 minutes on day 2 Other Names: Adriamycin® NSC #123127 (102004) Drug: Intrathecal chemotherapy IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration. 30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age. Other Names: Cytosine Arabinoside Ara-C Cytosar® NSC #63878 (102004)

Arm

Intervention/Treatment

Experimental: VLPD Regimen

Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.

Drug: Metformin

Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.

Drug: Vincristine

1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23

Other Names:

Oncovin®

VCR

LCR

NSC #67574

Drug: Dexamethasone

10 mg/m^2/day divided BID Take dexamethasone by mouth days 2-15

Other Names:

Decadron®

Hexadrol®

Dexone®

Dexameth®

NSC #34521 (112004)

Drug: PEG-asparaginase

2500 IU's/m^2/day Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23 If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis. Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol.

Other Names:

Oncaspar

NSC #644954

Pegaspargase

Oncaspar®

Polyethylene

Glycol Conjugated L-asparaginase-H

Drug: Doxorubicin

60 mg/m^2/day IV over 15 minutes on day 2

Other Names:

Adriamycin®

NSC #123127 (102004)

Drug: Intrathecal chemotherapy

IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration. 30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age.

Other Names:

Cytosine Arabinoside

Ara-C

Cytosar®

NSC #63878 (102004)

Outcome Measures

Primary Outcome Measures

Maximum Tolerated Dose (MTD) [45 days]
MTD determined by Dose Limiting Toxicity (DLT), any time during the first course of therapy. Dose Limiting Toxicities: Any Grade 3 or 4 non-hematological toxicity by Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0 felt to be probably or definitely related to the study agent, persistent marrow aplasia at day 44, lactic acidosis for grade 3 or 4, grade 3 and 4 hypoglycemia.

Secondary Outcome Measures

The Number of Participants with Complete Remission [45 days]
Patients who have: No evidence of circulating blasts or extramedullary disease; A bone marrow with <5% blasts (M1 marrow); and Recovery of peripheral counts (platelets ≥75,000 and absolute neutrophil count (ANC) ≥750) Qualifying marrow and peripheral counts should be performed within 1 week of each other
The Number of Participants with Biological Response to Treatment [45 days]
To evaluate the biological response of ALL blasts from children receiving metformin in a window fashion and in later time points.
The Number of Participants with Adverse Events as a Measure of Safety and Feasibility [45 Days]
To demonstrate the safety and feasibility of the addition of metformin to induction chemotherapy for recurrent ALL.

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year to 30 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

ALL or lymphoblastic lymphoma patients in first or higher relapse.
Male or Female age 1-30 years at initial diagnosis.
Signed informed consent.
Karnofsky / Lansky score above 50%.
No known contraindications to intended therapies.
Prior anthracycline exposure: Patients must have had less than 350 mg/m^2 lifetime exposure of anthracycline chemotherapy.
It must be at least 6 months since the last treatment with a "VPLD" induction/re-induction type regimen (i.e. anthracycline, steroid, asparaginase and vincristine).
Patients must have adequate organ function.
Adequate renal function defined as serum creatinine < 1.5 x upper limit of normal (ULN) for age.
Total bilirubin < 1.5 X ULN for age.
Alanine transaminase (ALT) < 5 X ULN for age, unless the elevation is disease-related.
Adequate cardiac function as defined as shortening fraction of > 27% by echocardiogram or ejection fraction > 45% by gated radionuclide study.

Exclusion Criteria:

Significant renal impairment as determined per investigator discretion.
Patients planning on receiving other investigational agents while on this study.
Patients planning on receiving other anti-cancer therapies while on this study.
Patients with active infection defined as: positive blood culture within 48 hours of study registration; need for supplemental oxygen or vasopressors within 48 hours of study entry.
Patient receiving corticosteroids, aside from dexamethasone treatment directed at leukemia.
Known intolerance to doxorubicin, metformin, or vincristine.
Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT therapy was given within 72 hours of study enrollment as part of the diagnostic lumbar procedure.
Patients may be on hydroxurea until the first dose of metformin is to be given.
Patients who have a need to continue hydroxurea while on study (Patients may continue on hydroxurea only until the first dose of metformin is to given).
Patients with creatinine more than 1.5 x the ULN
Patients must have recovered from the acute side effects of all prior anticancer therapy.
At least 1 week from prior cytotoxic chemotherapy.
At least 4 weeks from craniospinal irradiation.
At least 4 months since hematopoietic stem cell transplant (HSCT) with no evidence of active graft-versus-host disease (GVHD).
Pregnant or lactating women.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Holtz Children's Hospital University of Miami Miller School of Medicine	Miami	Florida	United States	33136
2	Arnold Palmer Hospital for Children	Orlando	Florida	United States	32806
3	All Children's Hospital	Saint Petersburg	Florida	United States	33701
4	Montefiore Medical Center, The Children's Hospital at Montefiore	The Bronx	New York	United States	10467
5	Nationwide Children's Hospital	Columbus	Ohio	United States	43205

Sponsors and Collaborators

H. Lee Moffitt Cancer Center and Research Institute
Pediatric Cancer Foundation

Investigators

Study Chair: Julio M. Barredo, M.D., Holtz Children's Hospital University of Miami Miller School of Medicine
Principal Investigator: Damon Reed, M.D., H. Lee Moffitt Cancer Center and Research Institute